secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2026-10-01T11:01:21+00:00
Accession:  0001628280-26-064102
Event type: other_material
Sentiment:  negative
Materiality: 0.78
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Foghorn, Lilly halt FHD-909 Phase 1 expansion; FHTX cuts 40% of staff, cash runway to 2H 2029
--------------------------------------------------------------------------------

- Foghorn and Eli Lilly will not advance FHD-909 (LY4050784) into the Phase 1 expansion phase after reviewing dose-escalation data; the selective SMARCA2 degrader program also ends.
- Workforce reduced by approximately 40%, with roughly 65 full-time employees expected after the cut; reduction substantially complete in Q4 2026.
- Charges of about $2.3 million, all future cash, primarily one-time severance and benefits in Q4 2026; runway extended into the second half of 2029.
- Remaining focus: selective EP300 degrader, novel oral immunology and inflammation program, selective CBP degrader, and induced proximity platform.
- CEO Adrian Gottschalk said SMARCA2/4 synthetic lethality biology did not translate into required efficacy; no further Lilly collaboration activities anticipated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/0001628280-26-064102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/fhtx-20260925.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-064102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer